Multibagger pharma stock at record high as analysts raise earnings estimates for next year post Q4 results
₹1,172.50 on the NSE on Tuesday. While a strong Q4 performance boosted Zydus Lifesciences share price, the strong growth guidance has given boost to earnings outlook said analysts.
Zydus Lifesciences revenue came in at ₹5,534 Crore in Q4, up 10.4% year-on-year. Its US business contributed well to growth and was supported by domestic business.
Its Earnings before interest tax depreciation and amortisation was at around ₹1630 crore also grew 23.7% year-on-year Its reported net profit at ₹1182 crore thereby grew multifold over ₹297 crore in the year ago quarter. Also Read- HDFC Securities bullish on healthcare sector; advises buying Apollo Hospitals, Medplus Health – here's why US sales grew 12% YoY (10.5% YoY in constant Currency terms) contributing slightly less than half of over all revenues .
The domestic sales (including wellness) contributing more than 40% of over all revenues , also grew 7% year-on-year in Q4. The management has guided for double digit growth in all markets, including domestic business, which as per analysts has led them raise looked at positively by analysts.
Read more on livemint.com
